Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774 · View on ClinicalTrials.gov ↗
Study Summary
This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INCA034176
- DRUG Corticosteroids
Study Locations (20)
Florida
- Miami Cancer Institute — Miami
- Orlando Health Cancer Institute Downtown Orlando — Orlando
- Memorial Cancer Institute — Pembroke Pines
Michigan
- University of Michigan — Ann Arbor
- Henry Ford Hospital — Detroit
- Corewell Health Hematology Oncology — Grand Rapids
California
- University of California San Diego Medical Center, Moores Cancer Center — La Jolla
- University of Southern California — Los Angeles
Massachusetts
- Massachusetts General Hospital — Boston
- Dana Farber Cancer Institute — Boston
New Jersey
- Hackensack University Medical Center — Hackensack
- Rutgers Cancer Institute of Nj — New Brunswick
New York
- University of Rochester Medical Center — Rochester
- Stony Brook University Medical Center — Stony Brook
Alabama
- University of Alabama Birmingham — Birmingham
Colorado
- Colorado Blood Cancer Institute — Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06585774
The ClinicalTrials.gov registry entry for NCT06585774 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 163 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Chronic Graft-versus-host-disease appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06585774 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Florida, Michigan, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06585774 about?
NCT06585774 is a clinical study titled "A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease". This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
What is the current status of trial NCT06585774?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2025-01-21. Estimated completion is 2030-03-31.
What conditions does trial NCT06585774 study?
This clinical trial studies the following conditions: Chronic Graft-versus-host-disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06585774?
The interventions under investigation include: Placebo (DRUG), INCA034176 (DRUG), Corticosteroids (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06585774?
This trial is sponsored by Incyte Corporation, which has 163 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06585774 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.